-
UN doubles appeal for Lebanon aid to nearly $640 mn amid Israel war
-
Sicily braces for post-wedding blowout of Dua Lipa, Callum Turner
-
Sooryavanshi, 15, in line for maiden India call-up: report
-
Japan change World Cup training sites in Mexico over conditions
-
Rescued orphaned elephant highlights Nigeria's conservation fight
-
Crypto scammers prey on French victims from Albania
-
Turkmenistan's 'heavenly' horses at the heart of fervent state cult
-
China's Xi to visit North Korea next week
-
'Extremely intelligent' bear at large in Japan after hurting four
-
Irish racing great O'Brien bids to make Epsom Derby history
-
Uzbekistan's debut World Cup crowns surge in football popularity
-
Australia seizes 100,000 cockroaches in bug-breeder bust
-
Kupcho seizes slim lead in US Women's Open at Riviera
-
Asian stocks take another hit from AI, Mideast worries
-
Game on: Trump set to attend game 3 of NBA Finals in New York
-
Nazi party records released online shatter German family myths
-
Political blows fly ahead of Trump's White House UFC fight
-
US allying itself with Colombian 'narco-traffickers,' Petro accuses
-
New York City's rules for AI in schools spark fury
-
Putin to confront weak economy at 'Russian Davos', under threat of Ukrainian drones
-
Australian far-right does U-turn on seizing foreigners' homes
-
Thousands protest in Albania against Kushner real estate project
-
Kiss confident Reds can 'scare' Chiefs in Super Rugby playoff
-
OCM Snack Festival Sparks Ultimate NYL AAPI Night Viral AIKO GARDEN 3D Fruit Ice Cream Sweeps Mainstream Market
-
InterContinental Hotels Group PLC Announces Transaction in Own Shares - June 05
-
Hemogenyx Pharmaceuticals PLC Announces Notice of AGM
-
US imposes sanctions on Cuban president, Castro family members
-
Clark, Spaun part of four-way tie for lead at Memorial tournament
-
Trump confirms mass rally, scrapping US 250th concerts
-
Anthropic calls for pause of global AI development
-
Wemby counts on 'normal' Spurs to bounce back in NBA Finals
-
LA Olympics boss Wasserman says will not step down over Epstein links
-
Dangerous livestock pest case confirmed in Texas
-
Diallo gives Ivory Coast shock win over France
-
Latest 'Scary Movie' aims to cancel 'cancel culture,' creators say
-
Selfie-seeking fan banned for life by NBA after crashing Finals game
-
Lyles reigns in Rome 100m, Pathirage stuns with javelin
-
German serial killer found guilty of murder of French schoolboy
-
Trump announces $700 mn support for US coal projects
-
Dissing critics with humor, Hunter Biden finds social media stardom
-
SpaceX IPO: rockets, AI losses and Musk in control
-
In open letter to Putin, Zelensky calls for meeting and ceasefire
-
Pakistan upstage Australia for 2-1 ODI series win
-
Liverpool appoint Spaniard Iraola as new boss
-
Andreeva stays focused to race past Kostyuk into French Open final
-
Qualifier Chwalinska sets up Andreeva French Open final clash
-
Colombia court bans pro-Trump candidate from using jersey as symbol
-
Unfazed Antonelli plans to race with freedom
-
Designer Gabriela Hearst still believes in 'brilliance of humanity' despite AI
-
North Israel residents hold little hope for Lebanon truce deal
Hemogenyx Pharmaceuticals PLC Announces Notice of AGM
Hemogenyx Pharmaceuticals plc
("Hemogenyx Pharmaceuticals" or the "Company")
Posting of Annual Report & Notice of Annual General Meeting
LONDON, UK / ACCESS Newswire / June 5, 2026 / Hemogenyx Pharmaceuticals plc (LSE:HEMO), the biopharmaceutical group, confirms that the Annual Report and Accounts for the year ended 31 December 2025, the Notice of the Annual General Meeting ("AGM") and a Form of Proxy will be posted to shareholders today and will shortly be available on the Company's website at https://hemogenyx.com/investors/annual-half-year-reports/.
The AGM is to be held on 30 June 2026 at 2.00 pm BST at One Heddon Street, London, W1B 4BD.
Enquiries:
Hemogenyx Pharmaceuticals plc | |
Dr Vladislav Sandler, Chief Executive Officer & Co-Founder | |
Peter Redmond, Director | |
SP Angel Corporate Finance LLP | Tel: +44 (0)20 3470 0470 |
Matthew Johnson, Vadim Alexandre, Adam Cowl | |
AlbR Capital Limited | Tel: +44 (0)20 7469 0930 |
Lucy Williams, Duncan Vasey, Charles Goodfellow | |
About Hemogenyx Pharmaceuticals plc
Hemogenyx Pharmaceuticals is a publicly traded company (LSE:HEMO) headquartered in London, with its US operating subsidiaries, Hemogenyx Pharmaceuticals LLC and Immugenyx LLC, located in New York City.
The Company is a clinical-stage biopharmaceutical group developing new medicines and treatments to treat blood and autoimmune diseases. Hemogenyx Pharmaceuticals is developing several distinct and complementary product candidates, as well as platform technologies that it uses as engines for novel product development.
This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [email protected] or visit www.rns.com.
SOURCE: Hemogenyx Pharmaceuticals plc
View the original press release on ACCESS Newswire
A.Mahlangu--AMWN